Table 2.
Disease characteristics
| Variable | Saudi Arabia n=206 | Turkey n=199 | Overall n=405 |
|---|---|---|---|
| Age at symptom onset (years) | |||
| Count | 201 | 199 | 400 |
| Mean (±SD) | 51.6 (±12.1) | 52.9 (±10.9) | 52.3 (±11.5) |
| Disease duration (years) | |||
| Count | 202 | 199 | 401 |
| Mean (±SD) | 11.7 (±10.0) | 8.3 (±7.5) | 10.0 (±9.0) |
| Time between symptom onset and diagnosis (years) | |||
| Count | 199 | 196 | 395 |
| Mean (±SD) | 3.4 (±5.5) | 2.4 (±5.9) | 2.9 (±5.7) |
| Exacerbations in the last 12 months, n (%) | |||
| Count | 199 | 199 | 398 |
| No | 77 (38.7) | 112 (56.3) | 189 (47.5) |
| Yes | 122 (61.3) | 87 (43.7) | 209 (52.5) |
| CAT score, n (%) | |||
| Count | 197 | 195 | 392 |
| <10 | 13 (6.6) | 41 (21.0) | 54 (13.8) |
| 10–15 | 32 (16.2) | 45 (23.1) | 77 (19.6) |
| >15 | 152 (77.2) | 109 (55.9) | 261 (66.6) |
| MRC dyspnea scale, n (%) | |||
| Count | 194 | 197 | 391 |
| MRC =1 | 13 (6.7) | 22 (11.2) | 35 (9.0) |
| MRC >1 | 181 (93.3) | 175 (88.8) | 356 (91.1) |
| EQ-5D-3L utility values | |||
| Count | 197 | 199 | 396 |
| Mean (±SD) | 0.52 (±0.37) | 0.66 (±0.27) | 0.59 (±0.33) |
| EQ-VAS score | |||
| Count | 205 | 198 | 403 |
| Mean (±SD) | 70.3 (±14.8) | 59.9 (±18.7) | 65.2 (±17.6) |
| HADS anxiety score, n (%) | |||
| Count | 195 | 197 | 392 |
| <8 | 96 (49.2) | 128 (65.0) | 224 (57.1) |
| 8–10 | 61 (31.3) | 35 (17.8) | 96 (24.5) |
| >10 | 38 (19.5) | 34 (17.3) | 72 (18.4) |
| HADS depression score, n (%) | |||
| Count | 193 | 197 | 390 |
| <8 | 70 (36.3) | 109 (55.3) | 179 (45.9) |
| 8–10 | 51 (26.4) | 51 (25.9) | 102 (26.2) |
| >10 | 72 (37.3) | 37 (18.8) | 109 (28.0) |
Notes: Disease characteristics of the study population. An exacerbation was defined as a hospitalization or emergency room visit.
Abbreviations: CAT, COPD Assessment Test; EQ-5D-3L, 3-level EuroQol Five-Dimension questionnaire; EQ-VAS, EuroQol Visual Analog Scale; HADS, Hospital Anxiety and Depression Scale; MRC, Medical Research Council.